Get to know our clinical trials
Neoadjuvant versus adjuvant chemotherapy in upper urinary tract urothelial carcinoma. Phase II randomized feasibility clinical trial.
THE AIM OF THIS STUDY IS TO EXPLORE THE FEASIBILITY OF UTUC TREATMENTS BASED ON CURRENT DATA FROM SEVERAL EUROPEAN COUNTRIES. WE WILL BE ABLE TO OBTAIN INFORMATION ON THE TRUE PROPORTION OF PATIENTS WHO ARE FIT TO RECEIVE AND COMPLETE NEOADJUVANT OR ADJUVANT CISPLATIN-BASED CHEMOTHERAPY, AND ON THE PROPORTION AND CLINICAL OUTCOME OF PATIENTS WITH POOR PROGNOSTIC FACTORS (PS AND RENAL FUNCTION) RECEIVING STANDARD TREATMENT ONLY (RNU).
Technical Summary
- NEOADJUVANT VERSUS ADJUVANT CHEMOTHERAPY IN UPPER URINARY TRACT UROTHELIAL CARCINOMA. PHASE II RANDOMIZED FEASIBILITY CLINICAL TRIAL
- Code EudraCT: 2016-004017-27
- Protocol number: URANUS
- Promoter: European Uro-Oncology Group (EUOG
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.